Company: CERO
Filing Date: 2025-12-02
Form Type: 8-K
Source: 0001213900-25-116971
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-02
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, CERo Therapeutics Holdings,
Inc., a Delaware corporation (the “ Company”) and an institutional investor (the “ Investor”) entered into a common
stock purchase agreement on each of February 14, 2024 (the “ February 2024 Purchase Agreement”), November 8, 2024 (the “ November
2024 Purchase Agreement”) and July 11, 2025 (the “ July 2025 Purchase Agreement” and, collectively with the February
2024 Purchase Agreement and November 2024 Purchase Agreement, the “ Prior Purchase Agreements”), pursuant to which, upon the
terms and subject to the conditions and limitations set forth in such Prior Purchase Agreements, the Company may issue and sell to the
Investor up to an aggregate of $25.0 million of the Company’s outstanding common stock, par value $0.0001 per share (the “ Common
Stock”). As of November 26, 2025, the Company has issued and sold (i) 11,689 shares of Common Stock for aggregate proceeds of approximately
$4.4 million pursuant to the February Purchase Agreement, (ii) 100,581 shares of Common Stock for aggregate proceeds of approximately
$3.1 million pursuant to the November Purchase Agreement and (iii) 12,500,000 shares of Common Stock for aggregate proceeds of approximately
$2.90 million pursuant to the July 2025 Purchase Agreement. Accordingly, in order to enable the Company to issue and sell and the Investor
to purchase from the Company, an aggregate of $25,000,000 of the Company’s outstanding shares of Common Stock, the Company and the
Investor have entered into the new Purchase Agreement described below.

On November 26, 2025, the Company entered into
a purchase agreement (the “ Purchase Agreement”) with the Investor, pursuant to which the Company may issue and sell to the
Investor, from time to time as provided in the Purchase Agreement, and the Investor shall purchase from the Company up to $14,591,939
of the Company’s outstanding shares of Common Stock, subject to the satisfaction of the conditions in the Purchase Agreement. Capitalized
terms not otherwise defined shall have the meaning ascribed to them in the Purchase Agreement.

As the Purchase Agreement constitutes a continuation
of the equity line program commenced under the Prior Purchase Agreement, the Commitment Shares issued to the Investor pursuant to the